A quiet revolution is unfolding at the intersection of medicine and appetite, as millions of Americans taking GLP-1 drugs like Ozempic are eating — and buying — measurably less. What began as a diabetes treatment has become a force reshaping the economics of hunger itself, placing an estimated $73 billion in global food industry value under pressure. The great food empires of the modern era, built on the reliable rhythm of human craving, must now reckon with a pharmacological intervention in that most ancient of drives.